Intellia Therapeutics Inc. (NTLA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 50% of 52W Range • RSI-14 at 53.4 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While NTLA currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.23) and Max Pain ($13.89) forces dealer call-delta covering toward $19.40.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Intellia Therapeutics Inc. (NTLA) slipped -0.68% to $13.23, trading at 50% of its 52-week range ($7.95 – $18.48). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Exelixis (EXEL) delivered earnings and revenue surprises of +5.62% and +0.86%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals Poster presentations to include
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno
Biogen (BIIB) delivered earnings and revenue surprises of +27.18% and +8.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
For questions about this article or underlying research, email help@trefis.com.
BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
Intellia Therapeutics has seen its stock fall sharply over several years, even as the business moves closer to potential commercialization of its gene editing therapies. This raises a clear question about whether the cur
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +16.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NTLA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NTLA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Intellia Therapeutics Inc. (NTLA) ranks #858 by composite RQD confidence (33/100, grade E) and #277 by equity capitalization ($1.85B). Within this direct 5-issuer industry benchmark cohort, NTLA leads on earnings valuation at N/A trailing P/E, while NEOG leads on capital efficiency and profitability with -0.6% ROIC and 46.9% gross margin. NEOG currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with NTLA at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NTLA
ACTIVE
Intellia Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -0.68% | $1.85B | Benchmark Subject |
| CLDX Celldex Therapeutics Inc. | D- | 41/100 | — | 87.1% | -35.0% | +0.78% | $2.35B | /cldx-vs-ntla → |
| NEOG Neogen Corporation | D+ | 52/100 | — | 46.9% | -0.6% | +1.16% | $2.68B | /neog-vs-ntla → |
| QDEL QuidelOrtho Corporation | E | 30/100 | — | — | -35.0% | -1.78% | $943.6M | /qdel-vs-ntla → |
| ACHV Achieve Life Sciences Inc. | D | 44/100 | — | — | -35.0% | +4.96% | $739.9M | /achv-vs-ntla → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Intellia Therapeutics Inc. (NTLA) reported GAAP revenue of $67.7M (+16.9% vs. FY2024 revenue of $57.9M , and +86.5% cumulative change since FY2023) , GAAP net income of -$412.7M, operating cash flow of -$394.7M, and free cash flow of -$395.9M (-11.6% YoY). On the balance sheet, NTLA closed FY2025 with $842.1M in total assets against $0 in total debt (Altman Z-Score: 1.17, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $67.7M | -$412.7M | -$394.7M | -$395.9M | $842.1M | — |
| FY2024 (FY) | 2024-12-31 | $57.9M | -$519.0M | -$348.9M | -$354.7M | $1.19B | — |
| FY2023 (FY) | 2023-12-31 | $36.3M | -$481.2M | -$394.1M | -$394.1M | — | — |
As of 2026-11-01, Intellia Therapeutics Inc. (NASDAQ: NTLA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $13.23 (-0.68% 1D, market cap $1.85B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NTLA ranks #858 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NTLA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $2.35B) and NEOG (Neogen Corporation) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -0.6%, cap $2.68B). Among the 5-stock peer group, NTLA leads on earnings multiple (N/A) while NEOG leads on capital efficiency (-0.6% ROIC).
Per NTLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652130), Intellia Therapeutics Inc. generated $67.7M in revenue (+16.9% YoY), -$412.7M in net income, and -$395.9M in free cash flow against $842.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NTLA last traded at $13.23 (-0.68% on volume of 4,703,882 shares), positioning the stock +8.18% above its 50-day simple moving average ($12.23) and +1.15% above its 200-day simple moving average ($13.08). Across its 52-week range of $7.95 to $18.48, NTLA sits at the 50.1% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.58 to $14.88).
Why NTLA Stock slipped -0.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.